Navigation Links
Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents
Date:9/10/2009

h we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2008; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may n
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: U.S. Department of Health and Human Services Joins Ad Council and Warner Bros. Pictures to Combat Childhood Overweight and Obesity
2. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
3. Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance
4. Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
5. Warner Chilcott Announces Earnings Release Date and Conference Call For Second Quarter 2009 Financial Results
6. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
7. Warner Chilcott to Present at Wachovias 19th Annual Mid-Year Equity Conference
8. Senators Webb and Warner Vote to Protect Americas Kids From Tobacco
9. Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference
10. Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
11. Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Severe weather can occur with little warning, so it’s ... of National Preparedness Month, Amica Insurance is offering the ... unexpected:, , Build an emergency supply kit. It ... gallon of water per person per day for at least 72 ... includes pets so your family knows what to do and where ...
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... -- Metformin, a drug commonly used to treat diabetes, ... hormone (TSH) among patients with an underactive thyroid, a ... TSH levels may be associated with heart problems and ... in this study. Among those in the study ... of low levels of thyroid-stimulating hormone per year compared ...
(Date:9/22/2014)... 22, 2014 The report segments ... end user, and geography. The equipment segment accounted ... equipment market, by product. However, the accessories segment ... in the forecast period, owing to the rising ... stimulation and ultrasound segments are the fastest-growing segments ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... 5.6 Onboard Software to Navigate the Safest, Most Fuel-Efficient Route and Protect ... the World,s Poor , ... Sunnyvale, Calif. (Vocus) March 16, 2009 -- ... , the leader in using hospital ships to deliver free, world-class health ...
... making great money is a reality. This year we focus on advancing ... Social Engineering. Spring ChicagoCon 2009 by TDCC features world-class security training followed ... career on the cutting edge of technology and the human mind. ... ...
... harm that often follows brain injury, researcher says, , , ... of Alzheimer,s disease drugs may prevent long-term damage from ... Georgetown University Medical Center researchers. , The drugs -- ... that accumulates in the brains of people with Alzheimer,s ...
... getaway destinations are affected, studies find , , SUNDAY, March 15 ... can be a burden on a family,s finances and even ... be presented in Washington, D.C., at the annual meeting of ... these common conditions can have a wide impact on a ...
... All-In-One Mobility Solutions , ... Blue ... proud to announce the branding of RACO,s Advanced Solutions Group ... area network design, RFID compliance and application software development services ...
... WILMINGTON, Del., March 14 Today AstraZeneca ... in response to the appointment of a new FDA ... Commissioner of the Food and Drug Administration. Dr. Hamburg ... will serve the agency well in these challenging times. ...
Cached Medicine News:Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 4Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 5Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 2Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 3Health News:Alzheimer's Drug May Someday Help Head Trauma Victims 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:RACO Brands Its Advanced Solutions Group 2Health News:AstraZeneca Applauds Appointment of New FDA Commissioner 2
(Date:9/22/2014)... Sept. 22, 2014  AbbVie (NYSE: ... studies evaluating potential new medicines in the company,s ... 2014 European Society of Medical Oncology (ESMO) Annual ... . Data being presented include results from ... efficacy of veliparib (ABT-888), a poly (adenosine diphosphate ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... NEW YORK , Sept. 22, ... has signed an exclusive, global license agreement with ... commercialization of its proprietary plasma fractionation process. Concurrently, ... and its intention to strategically refocus and rebrand ... plans to pursue a national listing for its ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) today reported ... Cash, cash equivalents, and investments at September 30, ... 31, 2010. Revenue for the third quarter of ... in the third quarter of 2010 primarily as a result of ...
... NEW YORK, Nov. 2, 2011 JDRF and The Leona ... largest non-government funders of type 1 diabetes (T1D) programs, announced ... a new level of cooperation between the organizations. The goal ... and development to deliver better treatments, devices, and diagnostics for ...
Cached Medicine Technology:Nektar Therapeutics Reports Third Quarter 2011 Financial Results 2Nektar Therapeutics Reports Third Quarter 2011 Financial Results 3Nektar Therapeutics Reports Third Quarter 2011 Financial Results 4Nektar Therapeutics Reports Third Quarter 2011 Financial Results 5Nektar Therapeutics Reports Third Quarter 2011 Financial Results 6Nektar Therapeutics Reports Third Quarter 2011 Financial Results 7Nektar Therapeutics Reports Third Quarter 2011 Financial Results 8JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 2JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 3JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 4
... Western Blot Kits provide a sensitive and ... Borrelia burgdorferi. Proteins from the spirochete are ... antigens are fractionated according to molecular weight ... in the presence of sodium dodecyl sulfate. ...
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH™ Single Use Loading Units....
Medicine Products: